BackKyverna Therapeutics Overview
Kyverna Therapeutics Inc.

Kyverna Therapeutics Return on Equity

Valuation check: KYTX's ROE is -118.5%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

-118.50%

Return on Equity

-118.50%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Kyverna Therapeutics (KYTX) FAQ

Kyverna Therapeutics (KYTX) currently reports a ROE of -118.5%. That is below the sector sector average of 11.3%. Use the charts on this page to explore Kyverna Therapeutics's ROE history and peer comparisons.

Kyverna Therapeutics's ROE of -118.5% is lower than the its sector sector average of 11.3%. That is roughly 1149.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Kyverna Therapeutics's current -118.5% should be judged against industry norms (sector average: 11.3%) and against KYTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -118.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Kyverna Therapeutics, and consider following KYTX for alerts when major investors trade the stock.